Amgen Inc. (NASDAQ:AMGN) Shares Sold by STF Management LP

STF Management LP lowered its position in Amgen Inc. (NASDAQ:AMGN) by 8.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,835 shares of the medical research company’s stock after selling 716 shares during the quarter. Amgen comprises approximately 1.1% of STF Management LP’s investment portfolio, making the stock its 22nd biggest holding. STF Management LP’s holdings in Amgen were worth $2,525,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in Amgen during the 3rd quarter worth $25,000. Hershey Financial Advisers LLC bought a new position in Amgen in the 2nd quarter valued at about $30,000. nVerses Capital LLC acquired a new position in Amgen during the 2nd quarter valued at about $31,000. Bbjs Financial Advisors LLC bought a new stake in shares of Amgen during the 2nd quarter worth about $33,000. Finally, Matrix Trust Co acquired a new stake in shares of Amgen in the 3rd quarter worth approximately $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Citigroup initiated coverage on Amgen in a report on Thursday, November 14th. They set a “neutral” rating and a $335.00 target price on the stock. Barclays boosted their price objective on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. Bank of America raised their target price on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. UBS Group dropped their price target on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, October 31st. Finally, StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen has an average rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Stock Up 0.7 %

Shares of AMGN stock opened at $289.77 on Friday. Amgen Inc. has a 12 month low of $260.68 and a 12 month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a market cap of $155.76 billion, a PE ratio of 37.10, a price-to-earnings-growth ratio of 2.50 and a beta of 0.60. The stock has a 50 day moving average of $317.28 and a 200-day moving average of $318.02.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the company earned $4.96 EPS. On average, equities analysts predict that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.11%. Amgen’s dividend payout ratio is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.